The Lymphoma, Leukemia, and Myeloma Congress delivers comprehensive, evidence-based education across the full spectrum of hematologic malignancies. Through expert-driven sessions, case-based discussions, and analysis of the most recent clinical data, attendees gain clear, clinically relevant direction for optimizing patient management. The meeting brings together leading investigators and practicing clinicians to provide balanced perspectives that support informed, confident treatment decisions in rapidly evolving disease settings.

What You Need to Know

What-You-Need-to-Know

    • What is the Lymphoma, Leukemia & Myeloma Congress?

      The Lymphoma, Leukemia & Myeloma Congress (LL&M Congress) is a leading hematology conference dedicated exclusively to lymphoma, leukemia, and multiple myeloma. The meeting provides evidence-based, clinically relevant education designed to help oncology professionals improve outcomes in hematologic malignancies.

    • What is the history of the Lymphoma, Leukemia & Myeloma Congress?

      Entering its 26th year, the Lymphoma, Leukemia & Myeloma Congress builds on a 25-year legacy of trusted hematology education. For more than two decades, the meeting has evolved alongside advances in targeted therapy, immunotherapy, cellular therapy, and precision medicine—remaining a consistent resource for clinicians treating blood cancers.

    • How is the Lymphoma, Leukemia & Myeloma Congress agenda developed?

      The agenda is developed by nationally recognized hematology-oncology experts. Sessions focus on the latest clinical trial data, updated treatment guidelines, and case-based discussions to ensure practical application in real-world oncology practice.

    • Who are the faculty at the Lymphoma, Leukemia & Myeloma Congress?

      Faculty include leading hematologists, medical oncologists, researchers, and advanced practice providers specializing in lymphoma, leukemia, and multiple myeloma. Speakers are selected for both clinical expertise and their ability to translate emerging data into actionable treatment strategies.

    • What makes the Lymphoma, Leukemia & Myeloma Congress different from other oncology conferences?

      Unlike broad oncology meetings, the Lymphoma, Leukemia & Myeloma Congress is focused entirely on hematologic malignancies. This concentrated format allows for deeper discussion of treatment sequencing, emerging therapies, adverse event management, and long-term disease management in blood cancers.

    • Who should attend the Lymphoma, Leukemia & Myeloma Congress?

      The meeting is designed for hematologists, medical oncologists, advanced practice providers (NPs and PAs), fellows, pharmacists, and oncology professionals involved in the care of patients with lymphoma, leukemia, and multiple myeloma. Clinicians attend to stay current on evolving standards of care and new therapeutic strategies in hematologic oncology.

    • What will I gain from attending the Lymphoma, Leukemia & Myeloma Congress?

      Attendees gain:

      • Clear guidance on integrating new clinical trial data into practice

      • Updated treatment strategies for lymphoma, leukemia, and multiple myeloma

      • Practical approaches to managing therapy-related toxicities

      • Confidence in applying emerging therapies in real-world settings

      The education is designed for immediate clinical impact.

    • Does the Lymphoma, Leukemia & Myeloma Congress support multidisciplinary oncology care?

      Yes. The meeting brings together physicians, advanced practice providers, pharmacists, and oncology team members to address collaborative decision-making, coordinated care delivery, and patient-centered treatment strategies across the continuum of hematologic malignancy care.

    • Why attend the Lymphoma, Leukemia & Myeloma Congress?

      For more than 25 years, the Lymphoma, Leukemia & Myeloma Congress has delivered focused, expert-led education in hematologic malignancies. Entering its 26th year, the meeting continues to provide high-impact, clinically grounded content that helps oncology professionals deliver evidence-based care in lymphoma, leukemia, and multiple myeloma.

Why Attend

Key Features

LL&M Congress

Compared to Other Hematology Meetings

Scope of Curriculum Covers the full spectrum of hematologic malignancies, including leukemia, lymphoma, myeloma, and CLL, through in-depth sessions on emerging data, frontline and relapsed/refractory management, and evolving standards of care. Other meetings may be disease-specific or focus narrowly on one malignancy, offering less cross-disciplinary perspective.
Educational Format Features a blend of expert-led lectures, panel discussions, and case-based presentations that connect evidence with clinical application. Each session is designed to translate new data into actionable treatment strategies. Many meetings rely on traditional lecture-only formats, providing limited opportunity for clinical dialogue or multidimensional case exploration.
Faculty Expertise Led by internationally recognized investigators and clinicians who are directly involved in current trials and frontline patient care, offering balanced, practical insights. Some programs feature fewer practicing clinicians or a narrower range of expert voices.
Integration Within the LL&M Ecosystem Serves as the cornerstone of the LL&M educational series, linking to the LL&M Winter Symposium and APP Institute for continuous learning and consistent messaging throughout the year. Most hematology meetings function as standalone events, without connection to complementary or follow-up educational opportunities.
Audience Engagement Designed for clinical relevance and discussion, with opportunities to engage through Q&A, panel dialogue, and case review. The environment encourages participation and peer learning. Often passive learning environments, where attendees primarily listen to lectures with minimal engagement.
Community & Continuity Builds a loyal, collaborative community of oncologists, hematologists, and APPs who return annually to exchange insights and advance patient care across disease areas. Many conferences operate as one-off events, lacking the sense of continuity or professional network that LL&M fosters.
Practical Takeaways Every session focuses on translating data into practice, giving attendees concrete guidance for patient management, sequencing decisions, and incorporating new agents. Attendees at other meetings often receive broad data overviews without clear translation into real-world clinical workflows.
Back to top